discovered a novel METTL16-SENP3-LTF signaling axis that can modulate ferroptosis and participate in the progression of HCC, becoming a promising therapeutic strategy by targeting this axis to disrupt ferroptosis and ferroptosis susceptibility (62). This evidence concerns the gene SENP3 and hepatocellular carcinoma.